Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis (original) (raw)

References

1. Schmidt C, Stallmach A (2005) Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 51(2):127–145
   PubMed CAS Google Scholar
2. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205
   Article PubMed CAS Google Scholar
3. Atreya I, Atreya R, Neurath MF (2008) NF-kappaB in inflammatory bowel disease. J Intern Med 263(6):591–596. doi:10.1111/j.1365-2796.2008.01953.x (Review)
   Article PubMed CAS Google Scholar
4. Kaser A, Tilg H (2008) Novel therapeutic targets in the treatment of IBD. Expert Opin Ther Targets 12(5):553–563. doi:10.1517/14728222.12.5.553
   Article PubMed CAS Google Scholar
5. Hanauer SB (1996) Inflammatory bowel disease. N Engl J Med 334(13):841–848. doi:10.1056/NEJM199603283341307 (Review)
   Article PubMed CAS Google Scholar
6. Pari L, Tewas D, Eckel J (2008) Role of curcumin in health and disease. Arch Physiol Biochem 114(2):127–149. doi:10.1080/13813450802033958 (Review)
   Article PubMed CAS Google Scholar
7. Kozuch PL, Hanauer SB (2008) Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 14(3):354–377. doi:10.3748/wjg.14.354 (Review)
   Article PubMed CAS Google Scholar
8. Billerey-Larmonier C, Uno JK, Larmonier N, Midura AJ, Timmermann B, Ghishan FK, Kiela PR (2008) Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis 14(6):780–793. doi:10.1002/ibd.20348
   Article PubMed Google Scholar
9. Holt PR, Katz S, Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50(11):2191–2193. doi:10.1007/s10620-005-3032-8
   Article PubMed Google Scholar
10. Boone DL, Ma A (2003) Connecting the dots from toll-like receptors to innate immune cells and inflammatory bowel disease. J Clin Invest 111(9):1284–1286
    PubMed CAS Google Scholar
11. Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216. doi:10.1146/annurev.immunol.20.083001.084359
    Article PubMed Google Scholar
12. Bou-Fersen AM, Anim JT, Khan I (2008) Experimental colitis is associated with ultrastructural changes in inflamed and uninflamed regions of the gastrointestinal tract. Med Princ Pract 17(3):190–196. doi:10.1159/000117791
    Article PubMed Google Scholar
13. Al-Jarallah A, Khan I, Oriowo MA (2008) Role of Ca2+-sensitization in attenuated carbachol-induced contraction of the colon in a rat model of colitis. Eur J Pharmacol 579(1–3):365–373. doi:10.1016/j.ejphar.2007.10.069
    Article PubMed CAS Google Scholar
14. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96(3):795–803
    PubMed CAS Google Scholar
15. Khan I, Oriowo MA, Anim JT (2005) Amelioration of experimental colitis by Na–H exchanger-1 inhibitor amiloride is associated with reversal of IL-1ss and ERK mitogen-activated protein kinase. Scand J Gastroenterol 40(5):578–585. doi:10.1080/00365520510012352
    Article PubMed CAS Google Scholar
16. Khan I (2002) Antisense inhibition of cyclooxygenase-2 causes a selective suppression of the Na+–H+ exchanger isoform 3 in rat kidney in experimental colitis. Nephron 91(1):120–128. doi:10.1159/000057613
    Article PubMed CAS Google Scholar
17. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78(3):206–209. doi:10.1111/1523-1747.ep12506462
    Article PubMed CAS Google Scholar
18. Khan I, Al-Awadi FM, Thomas N (2001) In vivo inhibition of cyclooxygenase-2 by a selective phosphorothioated oligonucleotide. Antisense Nucleic Acid Drug Dev 11(4):199–207. doi:10.1089/108729001317022205
    Article PubMed CAS Google Scholar
19. Wang K, Wan YJ (2008) Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood) 233(5):496–506. doi:10.3181/0708-MR-231 (Review)
    Article CAS Google Scholar
20. Hogaboam CM, Vallance BA, Kumar A, Addison CL, Graham FL, Gauldie J, Collins SM (1997) Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 100(11):2766–2776. doi:10.1172/JCI119823
    Article PubMed CAS Google Scholar
21. Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martínez C (2008) VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29(6):948–956. doi:10.1016/j.peptides.2008.01.019
    Article PubMed CAS Google Scholar
22. Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, Gomariz RP, Martínez C (2006) Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann N Y Acad Sci 1070:129–134. doi:10.1196/annals.1317.001
    Article PubMed CAS Google Scholar
23. Araki A, Kanai T, Ishikura T, Makita S, Uraushihara K, Iiyama R, Totsuka T, Takeda K, Akira S, Watanabe M (2005) MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 40:16–23. doi:10.1007/s00535-004-1492-9
    Article PubMed CAS Google Scholar

For further reading

1. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4(12):1502–1506
   Article PubMed CAS Google Scholar
2. Bremner P, Heinrich M (2002) Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 54(4):453–472 (Review)
   Article PubMed CAS Google Scholar
3. Jian YT, Wang JD, Mai GF, Zhang YL, Lai ZS (2004) Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis. Di Yi Jun Yi Da Xue Xue Bao 24(12):1353–1358 (Chinese)
   PubMed CAS Google Scholar
4. Fukata M, Abreu MT (2007) TLR4 signalling in the intestine in health and disease. Biochem Soc Trans 35(Pt 6):1473–1478 (Review)
   Article PubMed CAS Google Scholar
5. Zhang R, Li Y, Beck PL, McCafferty DM (2007) Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-) mice. Biochem Soc Trans 35(Pt 5):1375–1376 (Review)
   PubMed CAS Google Scholar
6. Cario E (2008) Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Inflamm Bowel Dis 14(3):411–421 (Review)
   Article PubMed Google Scholar
7. Santin I, Castellanos-Rubio A, Hualde I, Castaño L, Vitoria JC, Bilbao JR (2007) Toll-like receptor 4 (TLR4) gene polymorphisms in celiac disease. Tissue Antigens 70(6):495–498
   Article PubMed CAS Google Scholar
8. Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR (2007) Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 102(11):2504–2512
   Article PubMed CAS Google Scholar
9. Kullberg BJ, Ferwerda G, de Jong DJ, Drenth JP, Joosten LA, Van der Meer JW, Netea MG (2008) Crohn’s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology 123(4):600–605
   Article PubMed CAS Google Scholar
10. Heimesaat MM, Fischer A, Jahn HK, Niebergall J, Freudenberg M, Blaut M, Liesenfeld O, Schumann RR, Göbel UB, Bereswill S (2007) Exacerbation of murine ileitis by toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 56(7):941–948
    Article PubMed CAS Google Scholar
11. Ishihara S, Rumi MA, Ortega-Cava CF, Kazumori H, Kadowaki Y, Ishimura N, Kinoshita Y (2006) Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Curr Pharm Des 12(32):4215–4228 (Review)
    Article PubMed CAS Google Scholar
12. Barton GM, Medzhitov R (2003) Toll-like receptor signaling pathways. Science 300:1524–1525
    Article PubMed CAS Google Scholar
13. Baumgart DC, Dignass AU (2004) Current biological therapies for inflammatory bowel disease. Curr Pharm Des 10:4127–4147
    Article PubMed CAS Google Scholar
14. Beutler B (2002) TLR-4 as the mammalian endotoxin sensor. Curr Top Microbiol Immunol 270:109–120
    PubMed CAS Google Scholar
15. Furrie E, Macfarlane S, Thomson G, Macfarlane GT (2005) Toll-like receptors-2, -3, and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 115:565–574
    Article PubMed CAS Google Scholar
16. Guslandi M (2005) Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol 17:145–147
    Article PubMed CAS Google Scholar
17. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK (2003) Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139(2):209–218
    Article PubMed CAS Google Scholar
18. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995
    Article PubMed CAS Google Scholar
19. Kirschning CJ, Schumann RR (2002) TLR-2: cellular sensor for microbial and endogenous molecular patterns. Curr Top Microbiol Immunol 270:121–144
    PubMed CAS Google Scholar
20. Kuhl AA, Loddenkemper C, Westermann J, Hoffmann JC (2002) Role of gamma delta T cells in inflammatory bowel disease. Pathobiology 70:150–155
    Article PubMed Google Scholar

Download references